War on NHS reform

A Government White Paper on healthcare reform has caused Unison, Britain’s biggest public sector trade union (over 1.3 million members), to launch legal action against the
Government ‘as a matter of urgency’. The day after the paper was presented in July, NHS CEOs were instructed by NHS CEO Sir David Nicholson to implement the proposals ‘immediately’ - without being given time to comment on the reforms. This instruction, said Unison, was unlawful.

The Government also failed to consult the public over plans to change the NHS radically.

Among the changes presented by Health Secretary Andrew Lansley are the abolition of Primary Care Trusts and
Strategic Health Authorities, and giving more power to general practitioners to control where funds are spent.
Andy Burnham, Shadow Health Secretary and Labour leadership candidate, backed Unison: ‘There is no democratic mandate for the break-up of the NHS’, he said, adding that, as the Coalition Government’s agreement explicitly ruled out a top-down NHS reorganisation ‘these dangerous plans represent one of the biggest and quickest u-turns in political history.’

The reforms, he said, could cost billions of pounds at a time when cuts to frontline services are increasing. ‘GPs are
unprepared for it, NHS staff don’t want it and patients never asked for it.’

07.09.2010

Related articles

Photo

News • Concerns about hurried adoption

Survey: Is medical AI taking over too quickly?

The pace of artificial intelligence (AI) adoption in personalised medicine is unsettling for great parts of the public. A new survey reflects the worried state of mind in the UK.

Photo

Article • Sustainability

The challenge of "greening" medical technologies

Under the impulse of the European Commission, the in vitro diagnostic industry is developing emerging technologies to implement sustainable practices in medical laboratories. As sustainability has…

Photo

News • Sustainability assessment

EU laws need to look at the environmental impact of pharmaceuticals, study finds

Current EU regulation does not adequately consider the environmental emissions of pharmaceuticals in global manufacturing supply chains, a recent study from Finland concludes.

Subscribe to Newsletter